Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

Phase II results of VELCADE in patients with aggressive lymphoma published in Journal of Clinical Oncology

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

FDA approves 200 mg formulation of INTELENCE for HIV-1

FDA approves 200 mg formulation of INTELENCE for HIV-1

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

DARA's KRN5500 reduces allodynia in Phase 2a study for neuropathic pain in cancer patients

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Study comparing subcutaneous, intravenous administration of VELCADE in relapsed MM patients presented at ASH

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Research reveals new standard treatment options for various forms of lymphoma

Research reveals new standard treatment options for various forms of lymphoma

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

FDA approves Halaven therapy for metastatic late-stage breast cancer

FDA approves Halaven therapy for metastatic late-stage breast cancer

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

EpiCept third quarter net loss decreases to $3.2 million

EpiCept third quarter net loss decreases to $3.2 million

XenoPort third quarter net loss decreases to $19.9 million

XenoPort third quarter net loss decreases to $19.9 million

SGN-35 drug reduces tumor growth in Hodgkin's lymphoma

SGN-35 drug reduces tumor growth in Hodgkin's lymphoma

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

FDA approves Cymbalta for treatment of chronic musculoskeletal pain

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.